Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases.
Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising Chimpanzee Adenovirus (prime) and MVA (boost) is exceptional at inducing, boosting and maintaining CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licenced from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. Vaccitech currently has a Phase 2a clinical programme for prostate cancer and is poised to enter the clinic with HPV and NSCLC therapeutics. The company is also co-developing products for MERS coronavirus and Herpes Zoster with international collaborators and has outlicensed its rights to the ChAdOx COVID-19 vaccine to University of Oxford-AstraZeneca. Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.
+44 1865 818808